Core Insights - Pfizer (PFE.US) announced positive topline results for its long-acting injectable GLP-1 receptor agonist PF'3944 (MET-097i) in the phase 2 VESPER-3 study, targeting adults with obesity or overweight without type 2 diabetes [1][2] Group 1: Study Results - In the VESPER-3 study, patients in the first and third groups experienced weight reductions of 10% and 12.3% respectively compared to the placebo group by week 28, indicating sustained weight loss without reaching a plateau [1] - The treatment demonstrated a favorable safety profile consistent with GLP-1RA class drugs, with mostly mild to moderate gastrointestinal adverse events observed [2] Group 2: Drug Development Pipeline - Following the recent acquisition of Metsera and a global exclusive collaboration with YaoPharma, Pfizer has established a diversified pipeline of obesity candidates, including injectable and oral GLP-1 receptor-targeting drugs, GIPR agonists and antagonists, and insulin analogs [3] - Pfizer plans to advance a large-scale obesity development program, expecting to initiate over 20 clinical trials by 2026, including 10 phase 3 studies for PF'3944 [3]